Therapeutics based on stem cell technology, including stem cell-derived exosomes, have emerged in recent years for the treatment of what were otherwise considered incurable diseases. In this study, we evaluated the efficacy of human MSC-derived exosomes for protection against cisplatin induced ototoxic hearing loss. Incubation of cochlear explants with MSC-derived exosomes prior to addition of cisplatin induced a reduction in cisplatin-induced drug toxicity in auditory hair cells but not when the exosomes were introduced simultaneously with or after cisplatin. The delivery of MSC-derived exosomes to cochlear explants was confirmed by the increasing protein levels of the exosome markers CD63 and HSP70 to reduce apoptosis. These results were consistent with those from a model in which MSC-derived exosomes protect auditory hair cells from cisplatin-induced drug toxicity in an ex vivo cochlear explant model and support future studies into the therapeutic benefits of stem cell-derived exosomes in clinical applications.

近年来出现了基于干细胞技术的疗法，包括干细胞衍生的外泌体，用于治疗原本被认为无法治愈的疾病。在这项研究中，我们评估了人类 MSC 衍生的外泌体对顺铂诱导的耳毒性听力损失的保护作用。在添加顺铂之前将耳蜗外植体与 MSC 衍生的外泌体孵育可降低顺铂诱导的听觉毛细胞药物毒性，但当外泌体与顺铂同时或之后引入时则不会。通过增加外泌体标志物 CD63 和 HSP70 的蛋白质水平以减少细胞凋亡，证实了 MSC 衍生的外泌体向耳蜗外植体的递送。